Abstract
Gestational diabetes mellitus (GDM) is the most common pregnancy complication worldwide and is associated with short- and long-term health implications for both mother and child. Prevalence of GDM varies between ethnicities, with South Asians (SAs) experiencing up to three times the risk compared to white Europeans (WEs). This study aimed to evaluate the causal role of metabolic characteristics in the ethnic-associated differences in gestational dysglycemia.
A one-sample Mendelian Randomisation (MR) was performed separately on 3688 SA and 3354 WE women (<28th week of pregnancy) from the Born in Bradford (BiB) cohort for 146 metabolites exposures for the outcomes of fasting glucose and 2-hr post glucose (P ≤ 1 x 10-5 was considered significant). Additional GWAS and MR analyses on 22 composite measures of metabolite classes were also conducted.
Through an extensive GWAS analysis this study identified 15 novel genome-wide significant (GWS) SNPs associated with tyrosine in the FOXN and SLC13A2 genes and 1 novel GWS SNP (currently in no known gene) associated with acetate in SAs. Through the utilisation of a MR analysis, 14 metabolites were found to be associated with postprandial glucose in WEs, while in SAs a distinct panel of 11 metabolites were identified. Furthermore, in WEs, cholesterols were most the common metabolite associated with dysglycemia, while in SAs saturated fatty acids were most common. Furthermore, in SAs a composite measure of the fatty acid class was also found to associate with 2-hour post glucose.
The presence of ethnic-specific causal relationships between a comprehensive set of metabolites and postprandial glucose measures (fasting glucose and 2-hour post glucose) in mid-pregnancy has been established in a UK SA and WE population. Future work should aim to investigate the biological mechanisms of metabolites on GDM risk and inform ethnically tailored GDM prevention strategies are required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Wellcome UK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Bradford Research Ethnics Committee (ref07/H1302/112) of the University of Bradford gave ethnical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated title and text
Data Availability
All data produced in the present work are contained in the manuscript.